The authors wish to make the following corrections to this paper [1].
In Figure 1, all “SGLT-2i” should be replaced by “SU”. Correspondingly, in the figure legend, the definition of “SGLT-2i” should be removed.
Figure 1.
Flow chart of the sample selection process. DM, diabetes mellitus; DPP-4i, dipeptidyl-peptidase IV inhibitor; N, number; SU, sulfonylurea.
After correction, Figure 1 should be displayed as below:
The authors would like to apologize for any inconvenience caused to the readers by these changes.
Reference
- Kim, Y.G.; Jeon, J.; Kim, H.; Kim, D.; Lee, K.W.; Moon, S.; Han, S. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: A real-world population-based cohort study. J. Clin. Med. 2019, 8, 28. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).